UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Review Which Crypto Strategies Are Low Risk, focusing on capital preservation, diversification, and disciplined rebalancing.
27,978 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Investors weigh Amazon's Zoox-related progress against UPS's strategic shifts while oil volatility stirs the market. ...
As Iran-related conflict enters its fourth week, airlines brace for a fuel-cost shock even as travelers return and fa...
As markets wobble and political headwinds rise, a growing chorus argues that ceos have forgotten moderate. This piece...
The Nasdaq-100 has delivered eye-catching runs, but 2026 brought a pause. This guide breaks down what to watch, how t...
What looks like a bargain today could turn into a meaningful gain by 2026. This guide shows how patient investors ide...
AI growth drives data-center electricity demand, creating opportunities for energy players with long-term contracts. ...
A quiet crisis is forming in the real estate lending world. This article explains the $3 trillion challenge, who feel...
Rambus navigates a cooling memory-chip cycle that could weigh on margins even as AI infrastructure demand remains a k...
When a headline pairs two combat icons, it’s more than hype—it’s a blueprint for money decisions. This piece turns th...
When markets surge, two traps catch many investors off guard. This practical guide reveals the incredibly costly mist...
As Fed policy shifts and market volatility persists, analysts say the era of an automatic market backstop is fading. ...